ONL Therapeutics Employee Directory
Biotechnology ResearchMichigan, United States11-50 Employees
ONL Therapeutics is a clinical-stage biotechnology company focused on developing therapies to protect retinal cells and preserve vision in patients with retinal disease. Its approach targets Fas-mediated cell death to safeguard retinal tissue, with potential applications across conditions such as age-related macular degeneration, retinal detachment, glaucoma, and inherited retinal diseases. The company is building a platform of product candidates intended for use in a range of blinding diseases, aiming to halt or slow vision loss where current options are limited. Based in Ann Arbor, Michigan, the company operates with a relatively small to mid-sized team. In 2025, ONL Therapeutics participated in the FLORetina-ICOOR Congress and announced it would deliver podium presentations at EYENOVATE and the FLORetina-ICOOR Congress, reflecting ongoing involvement in the ophthalmology research community.